RESUMO
The great versatility of G protein-coupled receptors (GPCRs), in terms of both their ability to bind different types of ligands and initiate a large number of distinct cellular signaling events, remains incompletely understood. In recent years, the classical view of the nature and consequences of ligand binding to GPCRs has dramatically changed. The notion of functional selectivity, achieved through both biased ligands and allosteric modulators, has brought substantial new insight into our comprehension of the pluridimensionality of signaling achieved by GPCRs. Moreover, receptor heterodimerization adds another important dimension to the diversity of cellular responses controlled by GPCRs. Here, we review these considerations and discuss how they will impact the design of improved therapeutics.
Assuntos
Produtos Biológicos/farmacologia , Receptores Acoplados a Proteínas G/fisiologia , Transdução de Sinais/fisiologia , Regulação Alostérica , Sítio Alostérico , Refluxo Gastroesofágico/tratamento farmacológico , Infecções por HIV/tratamento farmacológico , Humanos , Hiperparatireoidismo Secundário/tratamento farmacológico , Ligantes , Isoformas de Proteínas/agonistas , Isoformas de Proteínas/antagonistas & inibidores , Isoformas de Proteínas/fisiologia , Multimerização Proteica , Estrutura Terciária de Proteína , Receptores Acoplados a Proteínas G/agonistas , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Transdução de Sinais/efeitos dos fármacosAssuntos
Canais de Cálcio Tipo L/metabolismo , Receptores Adrenérgicos beta 2/metabolismo , Transdução de Sinais , Agonistas de Receptores Adrenérgicos beta 2 , Albuterol/farmacologia , Animais , AMP Cíclico/metabolismo , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , Proteínas Heterotriméricas de Ligação ao GTP/metabolismo , Hipocampo , Isoproterenol/farmacologia , Ligantes , Substâncias Macromoleculares , Neurônios/efeitos dos fármacos , Neurônios/enzimologia , Neurônios/metabolismo , Fosforilação , Subunidades Proteicas , Ratos , Transdução de Sinais/efeitos dos fármacosRESUMO
beta-Arrestins bind agonist-activated G protein-coupled receptors (GPCRs) and mediate their desensitization and internalization. Although beta-arrestins dissociate from some receptors at the plasma membrane, such as the beta2 adrenergic receptor, they remain associated with other GPCRs and internalize with them into endocytic vesicles. Formation of stable receptor-beta-arrestin complexes that persist inside the cell impedes receptor resensitization, and the aberrant formation of these complexes may play a role in GPCR-based diseases (Barak, L. S., Oakley, R. H., Laporte, S. A., and Caron, M. G. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 93-98). Here, we investigate the molecular determinants responsible for sustained receptor/beta-arrestin interactions. We show in real time and in live human embryonic kidney (HEK-293) cells that a beta-arrestin-2-green fluorescent protein conjugate internalizes into endocytic vesicles with agonist-activated neurotensin-1 receptor, oxytocin receptor, angiotensin II type 1A receptor, and substance P receptor. Using receptor mutagenesis, we demonstrate that the ability of beta-arrestin to remain associated with these receptors is mediated by specific clusters of serine and threonine residues located in the receptor carboxyl-terminal tail. These clusters are remarkably conserved in their position within the carboxyl-terminal domain and serve as primary sites of agonist-dependent receptor phosphorylation. In addition, we identify a beta-arrestin mutant with enhanced affinity for the agonist-activated beta2-adrenergic receptor that traffics into endocytic vesicles with receptors that lack serine/threonine clusters and normally dissociate from wild-type beta-arrestin at the plasma membrane. By identifying receptor and beta-arrestin residues critical for the formation of stable receptor-beta-arrestin complexes, these studies provide novel targets for regulating GPCR responsiveness and treating diseases resulting from abnormal GPCR/beta-arrestin interactions.
Assuntos
Endocitose , Receptores de Superfície Celular/metabolismo , Sequência de Aminoácidos , Arrestinas/metabolismo , Linhagem Celular , Membrana Celular/metabolismo , Proteínas de Fluorescência Verde , Humanos , Proteínas Luminescentes/metabolismo , Microscopia Confocal , Microscopia de Fluorescência , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Mutação , Fosforilação , Plasmídeos/metabolismo , Ligação Proteica , Estrutura Terciária de Proteína , Receptor Tipo 1 de Angiotensina , Receptores de Angiotensina/metabolismo , Receptores da Neurocinina-1/metabolismo , Receptores de Neurotensina/metabolismo , Receptores de Ocitocina/metabolismo , Proteínas Recombinantes de Fusão/metabolismo , Homologia de Sequência de Aminoácidos , Fatores de Tempo , Transfecção , beta-Arrestina 2 , beta-ArrestinasRESUMO
Agonist-dependent desensitization and internalization of G protein-coupled receptors (GPCR) are mediated by the binding of arrestins to phosphorylated receptors. The affinity of arrestins for the phosphorylated GPCR regulates the ability of the internalized receptor to be dephosphorylated and recycled back to the plasma membrane. In this study, we show that the naturally occurring loss of function vasopressin receptor mutation R137H, which is associated with familial nephrogenic diabetes insipidus, induces constitutive arrestin-mediated desensitization. In contrast to the wild-type vasopressin receptor, the nonsignaling R137H receptor is phosphorylated and sequestered in arrestin-associated intracellular vesicles even in the absence of agonist. Eliminating molecular determinants on the receptor that promote high affinity arrestin-receptor interaction reestablishes plasma membrane localization and the ability of the mutated receptors to signal. These findings suggest that unregulated desensitization can contribute to the etiology of a GPCR-based disease, implying that pharmacological targeting of GPCR desensitization may be therapeutically beneficial.
Assuntos
Arrestinas/metabolismo , Diabetes Insípido Nefrogênico/genética , Mutação/genética , Receptores de Vasopressinas/metabolismo , Adenilil Ciclases/metabolismo , Substituição de Aminoácidos , Arginina Vasopressina/farmacologia , Linhagem Celular , Membrana Celular/metabolismo , Dinaminas , Endocitose , GTP Fosfo-Hidrolases/genética , GTP Fosfo-Hidrolases/metabolismo , Humanos , Microscopia de Fluorescência , Fenótipo , Fosforilação , Testes de Precipitina , Ligação Proteica , Receptores de Vasopressinas/genética , Proteínas Recombinantes , Transdução de Sinais , Transfecção , beta-ArrestinasRESUMO
beta-Arrestins, originally discovered in the context of heterotrimeric guanine nucleotide binding protein-coupled receptor (GPCR) desensitization, also function in internalization and signaling of these receptors. We identified c-Jun amino-terminal kinase 3 (JNK3) as a binding partner of beta-arrestin 2 using a yeast two-hybrid screen and by coimmunoprecipitation from mouse brain extracts or cotransfected COS-7 cells. The upstream JNK activators apoptosis signal-regulating kinase 1 (ASK1) and mitogen-activated protein kinase (MAPK) kinase 4 were also found in complex with beta-arrestin 2. Cellular transfection of beta-arrestin 2 caused cytosolic retention of JNK3 and enhanced JNK3 phosphorylation stimulated by ASK1. Moreover, stimulation of the angiotensin II type 1A receptor activated JNK3 and triggered the colocalization of beta-arrestin 2 and active JNK3 to intracellular vesicles. Thus, beta-arrestin 2 acts as a scaffold protein, which brings the spatial distribution and activity of this MAPK module under the control of a GPCR.
Assuntos
Arrestinas/metabolismo , MAP Quinase Quinase 4 , MAP Quinase Quinase Quinases/metabolismo , Sistema de Sinalização das MAP Quinases , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Proteínas Tirosina Quinases/metabolismo , Receptores de Angiotensina/metabolismo , Angiotensina II/metabolismo , Angiotensina II/farmacologia , Animais , Arrestinas/genética , Células COS , Linhagem Celular , Núcleo Celular/metabolismo , Citosol/enzimologia , Citosol/metabolismo , Endossomos/enzimologia , Endossomos/metabolismo , Ativação Enzimática , Humanos , MAP Quinase Quinase Quinase 5 , Camundongos , Proteína Quinase 10 Ativada por Mitógeno , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Mutação , Fosforilação , Proteínas Proto-Oncogênicas c-jun/metabolismo , Ratos , Receptor Tipo 1 de Angiotensina , Proteínas Recombinantes de Fusão/metabolismo , Transfecção , Técnicas do Sistema de Duplo-Híbrido , beta-Arrestina 2 , beta-ArrestinasRESUMO
An angiotensin II (AngII) peptidic analogue in which the third residue (valine) was substituted with the photoreactive p-benzoyl-L-phenylalanine (Bpa) was used to identify ligand-binding sites of the human AT(1) receptor. High-affinity binding of the analogue, (125)I-[Bpa(3)]AngII, to the AT(1) receptor heterologously expressed in COS-7 cells enabled us to efficiently photolabel the receptor. Chemical and enzymatic digestions of the (125)I-[Bpa(3)]AngII-AT(1) complex were performed, and receptor fragments were analyzed in order to define the region of the receptor with which the ligand interacts. Results show that CNBr hydrolysis of the photolabeled receptor gave a glycosylated fragment which, after PNGase-F digestion, migrated as a 11.4 kDa fragment, circumscribing the labeled domain between residues 143-243 of the AT(1) receptor. Digestion of the receptor-ligand complex with Endo Lys-C or trypsin followed by PNGase-F treatment yielded fragments of 7 and 4 kDa, defining the labeling site of (125)I-[Bpa(3)]AngII within residues 168-199 of the AT(1) receptor. Photolabeling of three mutant receptors in which selected residues adjacent to residue 168 were replaced by methionine within the 168-199 fragment (I172M, T175M, and I177M) followed by CNBr cleavage revealed that the bound photoligand (125)I-[Bpa(3)]AngII forms a covalent bond with the side chain of Met(172) of the second extracellular loop of the AT(1) receptor. These data coupled with previously obtained results enable us to propose a model whereby AngII adopts an extended beta-strand conformation when bound to the receptor and would orient itself within the binding domain by having its N-terminal portion interacting with the second extracellular loop and its C-terminus interacting with residues of the seventh transmembrane domain.
Assuntos
Angiotensina II/metabolismo , Receptores de Angiotensina/metabolismo , Sequência de Aminoácidos , Angiotensina II/análogos & derivados , Sítios de Ligação , Humanos , Ligantes , Modelos Moleculares , Dados de Sequência Molecular , Fenilalanina/análogos & derivados , Marcadores de Fotoafinidade , Receptor Tipo 1 de Angiotensina , Receptor Tipo 2 de Angiotensina , Receptores de Angiotensina/química , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismoRESUMO
Beta-arrestins are cytosolic proteins that regulate the signaling and the internalization of G protein-coupled receptors (GPCRs). Although termination of receptor coupling requires beta-arrestin binding to agonist-activated receptors, GPCR endocytosis involves the coordinate interactions between receptor-beta-arrestin complexes and other endocytic proteins such as adaptor protein 2 (AP-2) and clathrin. Clathrin interacts with a conserved motif in the beta-arrestin C-terminal tail; however, the specific molecular determinants in beta-arrestin that bind AP-2 have not been identified. Moreover, the respective contributions of the interactions of beta-arrestin with AP-2 and clathrin toward the targeting of GPCRs to clathrin-coated vesicles have not been established. Here, we identify specific arginine residues (Arg(394) and Arg(396)) in the beta-arrestin 2 C terminus that mediate beta-arrestin binding to AP-2 and show, in vitro, that these domains in beta-arrestin 1 and 2 interact equally well with AP-2 independently of clathrin binding. We demonstrate in HEK 293 cells by fluorescence microscopy that beta(2)-adrenergic receptor-beta-arrestin complexes lacking the beta-arrestin-clathrin binding motif are still targeted to clathrin-coated pits. In marked contrast, receptor-beta-arrestin complexes lacking the beta-arrestin/AP-2 interactions are not effectively compartmentalized in punctated areas of the plasma membrane. These results reveal that the binding of a receptor-beta-arrestin complex to AP-2, not to clathrin, is necessary for the initial targeting of beta(2)-adrenergic receptor to clathrin-coated pits.
Assuntos
Arrestinas/metabolismo , Clatrina/metabolismo , Invaginações Revestidas da Membrana Celular/metabolismo , Proteínas de Membrana/metabolismo , Receptores Adrenérgicos beta 2/metabolismo , Subunidades alfa do Complexo de Proteínas Adaptadoras , Proteínas Adaptadoras de Transporte Vesicular , Sequência de Aminoácidos , Arrestinas/química , Dados de Sequência Molecular , Ligação Proteica , Homologia de Sequência de Aminoácidos , beta-ArrestinasRESUMO
Visual arrestin, betaarrestin1, and betaarrestin2 comprise a family of intracellular proteins that desensitize G protein-coupled receptors (GPCRs). In addition, betaarrestin1 and betaarrestin2 target desensitized receptors to clathrin-coated pits for endocytosis. Whether arrestins differ in their ability to interact with GPCRs in cells is not known. In this study, we visualize the interaction of arrestin family members with GPCRs in real time and in live cells using green fluorescent protein-tagged arrestins. In the absence of agonist, visual arrestin and betaarrestin1 were found in both the cytoplasm and nucleus of HEK-293 cells, whereas betaarrestin2 was found only in the cytoplasm. Analysis of agonist-mediated arrestin translocation to multiple GPCRs identified two major classes of receptors. Class A receptors (beta2 adrenergic receptor, mu opioid receptor, endothelin type A receptor, dopamine D1A receptor, and alpha1b adrenergic receptor) bound betaarrestin2 with higher affinity than betaarrestin1 and did not interact with visual arrestin. In contrast, class B receptors (angiotensin II type 1A receptor, neurotensin receptor 1, vasopressin V2 receptor, thyrotropin-releasing hormone receptor, and substance P receptor) bound both betaarrestin isoforms with similar high affinities and also interacted with visual arrestin. Switching the carboxyl-terminal tails of class A and class B receptors completely reversed the affinity of each receptor for the visual and non-visual arrestins. In addition, exchanging the betaarrestin1 and betaarrestin2 carboxyl termini reversed their extent of binding to class A receptors as well as their subcellular distribution. These results reveal for the first time marked differences in the ability of arrestin family members to bind GPCRs at the plasma membrane. Moreover, they show that visual arrestin can interact in cells with GPCRs other than rhodopsin. These findings suggest that GPCR signaling may be differentially regulated depending on the cellular complement of arrestin isoforms and the ability of arrestins to interact with other cellular proteins.
Assuntos
Arrestinas/metabolismo , Proteínas de Ligação ao GTP/metabolismo , Receptores de Superfície Celular/metabolismo , Transporte Biológico , Linhagem Celular , Humanos , Mutação , Fosforilação , Ligação Proteica , Receptores de Superfície Celular/genéticaRESUMO
Resensitization of G protein-coupled receptors (GPCRs) following agonist-mediated desensitization is a necessary step for maintaining physiological responsiveness. However, the molecular mechanisms governing the nature of GPCR resensitization are poorly understood. Here, we examine the role of beta-arrestin in the resensitization of the beta(2) adrenergic receptor (beta(2)AR), known to recycle and resensitize rapidly, and the vasopressin V2 receptor (V2R), known to recycle and resensitize slowly. Upon agonist activation, both receptors recruit beta-arrestin to the plasma membrane and internalize in a beta-arrestin- and clathrin-dependent manner. However, whereas beta-arrestin dissociates from the beta(2)AR at the plasma membrane, it internalizes with the V2R into endosomes. The differential trafficking of beta-arrestin and the ability of these two receptors to dephosphorylate, recycle, and resensitize is completely reversed when the carboxyl-terminal tails of these two receptors are switched. Moreover, the ability of beta-arrestin to remain associated with desensitized GPCRs during clathrin-mediated endocytosis is mediated by a specific cluster of phosphorylated serine residues in the receptor carboxyl-terminal tail. These results demonstrate that the interaction of beta-arrestin with a specific motif in the GPCR carboxyl-terminal tail dictates the rate of receptor dephosphorylation, recycling, and resensitization, and thus provide direct evidence for a novel mechanism by which beta-arrestins regulate the reestablishment of GPCR responsiveness.
Assuntos
Arrestinas/metabolismo , Clatrina/metabolismo , Endocitose , Receptores de Superfície Celular/fisiologia , Sequência de Aminoácidos , Animais , Células COS , Linhagem Celular , Humanos , Dados de Sequência Molecular , Fosforilação , Receptores de Vasopressinas/metabolismo , Proteínas Recombinantes de Fusão/metabolismo , beta-ArrestinasRESUMO
beta-Arrestins are multifunctional proteins identified on the basis of their ability to bind and uncouple G protein-coupled receptors (GPCR) from heterotrimeric G proteins. In addition, beta-arrestins play a central role in mediating GPCR endocytosis, a key regulatory step in receptor resensitization. In this study, we visualize the intracellular trafficking of beta-arrestin2 in response to activation of several distinct GPCRs including the beta2-adrenergic receptor (beta2AR), angiotensin II type 1A receptor (AT1AR), dopamine D1A receptor (D1AR), endothelin type A receptor (ETAR), and neurotensin receptor (NTR). Our results reveal that in response to beta2AR activation, beta-arrestin2 translocation to the plasma membrane shares the same pharmacological profile as described for receptor activation and sequestration, consistent with a role for beta-arrestin as the agonist-driven switch initiating receptor endocytosis. Whereas redistributed beta-arrestins are confined to the periphery of cells and do not traffic along with activated beta2AR, D1AR, and ETAR in endocytic vesicles, activation of AT1AR and NTR triggers a clear time-dependent redistribution of beta-arrestins to intracellular vesicular compartments where they colocalize with internalized receptors. Activation of a chimeric AT1AR with the beta2AR carboxyl-terminal tail results in a beta-arrestin membrane localization pattern similar to that observed in response to beta2AR activation. In contrast, the corresponding chimeric beta2AR with the AT1AR carboxyl-terminal tail gains the ability to translocate beta-arrestin to intracellular vesicles. These results demonstrate that the cellular trafficking of beta-arrestin proteins is differentially regulated by the activation of distinct GPCRs. Furthermore, they suggest that the carboxyl-tail of the receptors might be involved in determining the stability of receptor/betaarrestin complexes and cellular distribution of beta-arrestins.
Assuntos
Arrestinas/metabolismo , Endocitose , Proteínas de Ligação ao GTP/metabolismo , Receptores de Superfície Celular/metabolismo , Linhagem Celular , Proteínas de Fluorescência Verde , Humanos , Proteínas Luminescentes/metabolismo , Proteínas Recombinantes de Fusão/metabolismo , beta-ArrestinasRESUMO
To identify ligand-binding domains of Angiotensin II (AngII) type 1 receptor (AT1), two different radiolabeled photoreactive AngII analogs were prepared by replacing either the first or the last amino acid of the octapeptide by p-benzoyl-L-phenylalanine (Bpa). High yield, specific labeling of the AT1 receptor was obtained with the 125I-[Sar1,Bpa8]AngII analog. Digestion of the covalent 125I-[Sar1,Bpa8]AngII-AT1 complex with V8 protease generated two major fragments of 15.8 kDa and 17.8 kDa, as determined by SDS-PAGE. Treatment of the [Sar1,Bpa8]AngII-AT1 complex with cyanogen bromide produced a major fragment of 7.5 kDa which, upon further digestion with endoproteinase Lys-C, generated a fragment of 3.6 kDa. Since the 7.5-kDa fragment was sensitive to hydrolysis by 2-nitro-5-thiocyanobenzoic acid, we circumscribed the labeling site of 125I-[Sar1,Bpa8]AngII within amino acids 285 and 295 of the AT1 receptor. When the AT1 receptor was photolabeled with 125I-[Bpa1]AngII, a poor incorporation yield was obtained. Cleavage of the labeled receptor with endoproteinase Lys-C produced a glycopeptide of 31 kDa, which upon deglycosylation showed an apparent molecular mass of 7.5 kDa, delimiting the labeling site of 125I-[Bpa1]AngII within amino acids 147 and 199 of the AT1 receptor. CNBr digestion of the hAT1 I165M mutant receptor narrowed down the labeling site to the fragment 166-199. Taken together, these results indicate that the seventh transmembrane domain of the AT1 receptor interacts strongly with the C-terminal amino acid of [Sar1, Bpa8]AngII interacts with the second extracellular loop of the AT1 receptor.
Assuntos
Angiotensina II/análogos & derivados , Fenilalanina/análogos & derivados , Marcadores de Fotoafinidade/química , Receptores de Angiotensina/metabolismo , Angiotensina II/química , Animais , Sítios de Ligação , Ligação Competitiva , Células COS/metabolismo , Células Cultivadas/metabolismo , Humanos , Radioisótopos do Iodo , Fenilalanina/química , Receptor Tipo 1 de Angiotensina , Receptor Tipo 2 de Angiotensina , Receptores de Angiotensina/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Sarcosina/químicaRESUMO
betaarrestins mediate the desensitization of the beta2-adrenergic receptor (beta2AR) and many other G protein-coupled receptors (GPCRs). Additionally, betaarrestins initiate the endocytosis of these receptors via clathrin coated-pits and interact directly with clathrin. Consequently, it has been proposed that betaarrestins serve as clathrin adaptors for the GPCR family by linking these receptors to clathrin lattices. AP-2, the heterotetrameric clathrin adaptor protein, has been demonstrated to mediate the internalization of many types of plasma membrane proteins other than GPCRs. AP-2 interacts with the clathrin heavy chain and cytoplasmic domains of receptors such as those for epidermal growth factor and transferrin. In the present study we demonstrate the formation of an agonist-induced multimeric complex containing a GPCR, betaarrestin 2, and the beta2-adaptin subunit of AP-2. beta2-Adaptin binds betaarrestin 2 in a yeast two-hybrid assay and coimmunoprecipitates with betaarrestins and beta2AR in an agonist-dependent manner in HEK-293 cells. Moreover, beta2-adaptin translocates from the cytosol to the plasma membrane in response to the beta2AR agonist isoproterenol and colocalizes with beta2AR in clathrin-coated pits. Finally, expression of betaarrestin 2 minigene constructs containing the beta2-adaptin interacting region inhibits beta2AR endocytosis. These findings point to a role for AP-2 in GPCR endocytosis, and they suggest that AP-2 functions as a clathrin adaptor for the endocytosis of diverse classes of membrane receptors.
Assuntos
Subunidades beta do Complexo de Proteínas Adaptadoras/fisiologia , Arrestinas/fisiologia , Endocitose/fisiologia , Proteínas de Membrana/fisiologia , Receptores Adrenérgicos beta 2/fisiologia , Subunidades alfa do Complexo de Proteínas Adaptadoras , Subunidades beta do Complexo de Proteínas Adaptadoras/química , Subunidades beta do Complexo de Proteínas Adaptadoras/genética , Proteínas Adaptadoras de Transporte Vesicular , Sequência de Aminoácidos , Animais , Arrestinas/genética , Células COS , Linhagem Celular , Clonagem Molecular , Proteínas de Fluorescência Verde , Humanos , Proteínas Luminescentes/biossíntese , Proteínas Luminescentes/química , Proteínas Luminescentes/genética , Substâncias Macromoleculares , Proteínas de Membrana/química , Proteínas de Membrana/genética , Dados de Sequência Molecular , Receptores Adrenérgicos beta 2/genética , Proteínas Recombinantes de Fusão/biossíntese , Saccharomyces cerevisiae , Transfecção , beta-ArrestinasRESUMO
G protein-coupled receptor kinase 5 (GRK5) is a member of a family of enzymes that phosphorylate activated G protein-coupled receptors (GPCR). To address the physiological importance of GRK5-mediated regulation of GPCRs, mice bearing targeted deletion of the GRK5 gene (GRK5-KO) were generated. GRK5-KO mice exhibited mild spontaneous hypothermia as well as pronounced behavioral supersensitivity upon challenge with the nonselective muscarinic agonist oxotremorine. Classical cholinergic responses such as hypothermia, hypoactivity, tremor, and salivation were enhanced in GRK5-KO animals. The antinociceptive effect of oxotremorine was also potentiated and prolonged. Muscarinic receptors in brains from GRK5-KO mice resisted oxotremorine-induced desensitization, as assessed by oxotremorine-stimulated [5S]GTPgammaS binding. These data demonstrate that elimination of GRK5 results in cholinergic supersensitivity and impaired muscarinic receptor desensitization and suggest that a deficit of GPCR desensitization may be an underlying cause of behavioral supersensitivity.
Assuntos
Proteínas de Ligação ao GTP/metabolismo , Proteínas Serina-Treonina Quinases/deficiência , Proteínas Serina-Treonina Quinases/genética , Receptores Muscarínicos/fisiologia , Analgésicos/farmacologia , Animais , Comportamento Animal/efeitos dos fármacos , Western Blotting , Temperatura Corporal/efeitos dos fármacos , Química Encefálica/efeitos dos fármacos , Quinase 5 de Receptor Acoplado a Proteína G , Guanosina 5'-O-(3-Tiotrifosfato)/farmacologia , Camundongos , Camundongos Knockout , Atividade Motora/efeitos dos fármacos , Agonistas Muscarínicos/farmacologia , Oxotremorina/farmacologia , Medição da Dor/efeitos dos fármacos , Receptores Muscarínicos/efeitos dos fármacos , Recombinação GenéticaRESUMO
The purpose of this study was to compare the efficiency of two different Gq protein-coupled receptors (AT1 receptor for angiotensin II and B2 receptor for bradykinin) to activate phospholipase C (PLC). When the receptors were expressed at a similar level of 0.5 pmol/mg of protein, inositol trisphosphate (IP) accumulation elicited by AT1 receptor was four times higher than that elicited by B2 receptor. Genistein and pertussis toxin did not modify AT1 receptor- or B2 receptor-induced IP accumulation. These results indicate that in COS-7 cells, the two receptors activate PLC beta through G proteins of the Gq family. AT1 or B2 receptors were co-expressed with the alpha subunit of either Gq or G11. Both alpha subunits potentiated to the same extent AT1 receptor-induced IP accumulation. alpha 11 was also as efficient as alpha q to potentiate B2 receptor-induced response. Interestingly, however, the potentiating effect of alpha q and alpha 11 was more important (by 5-fold) on AT1 receptor-mediated response than on B2 receptor-mediated response. These results demonstrate that the extent of activation of PLC beta by different Gq-coupled receptors depends on the level of expression of these receptors and on their coupling efficiency. These are important parameters that determine the relative contribution of specific hormones to different biological processes.
Assuntos
Proteínas de Ligação ao GTP/metabolismo , Receptores de Angiotensina/metabolismo , Receptores da Bradicinina/metabolismo , Animais , Células COS , Chlorocebus aethiops , Ativação Enzimática , Subunidades alfa Gq-G11 de Proteínas de Ligação ao GTP , Fosfatos de Inositol/metabolismo , Receptor Tipo 1 de Angiotensina , Receptor Tipo 2 de Angiotensina , Receptor B2 da Bradicinina , Receptores de Angiotensina/genética , Receptores da Bradicinina/genética , Proteínas Recombinantes/metabolismo , Transdução de Sinais , Fosfolipases Tipo C/metabolismoAssuntos
Proteínas de Ligação ao GTP/metabolismo , Proteínas Luminescentes/metabolismo , Receptores de Superfície Celular/metabolismo , Transdução de Sinais , Arrestinas/química , Divisão Celular , Proteínas de Fluorescência Verde , Humanos , Ligantes , Fosforilação , Transporte Proteico , Receptores de Superfície Celular/química , Proteínas Recombinantes de Fusão/metabolismo , Fatores de Tempo , beta-ArrestinasRESUMO
The angiotensin II (Ang II) type I receptor (AT1) is a member of the superfamily of heptahelical, G protein-coupled receptors (GPCRs) characterized by hydrophobic transmembrane domains connected by extra- and intracellular hydrophilic loops. The third intracellular loop (IC3) of many GPCRs is thought to directly interact with G proteins. We examined the molecular environment of the basic sequence KA221L222KK found in the IC3 of the human AT1 (hAT1) receptor by substituting Ala221 for Glu/Gln or Leu222 for Arg/Gln and determined the pharmacological properties of the resulting mutant receptors. Competitive binding experiments with the antagonist [Sar1,Ile8]Ang II revealed that COS-7 or stably expressing CHO cells transfected with either the wild-type or mutant receptors, produced a single population of high affinity binding sites (Kd of 0.5 nM) but variable receptor levels depending on cell type; Bmax approximately 100,000 sites/cell (COS-7), approximately 20,000 sites/cell (CHO). However, in competitive binding experiments using the agonist Ang II, both the wild type and the Ala-->Glu mutant displayed binding affinities of 1 nM, while the Leu-->Arg mutant had a significantly lower affinity (4 nM). When the functionality of the mutant receptors was examined, a lowered production of inositol-1,4,5-trisphosphate was obtained upon stimulation of the Ala-->Glu and Ala-->Gln mutants when compared to the wild-type receptor. However, no significant production of Ins(1,4,5)P3 was detected for the Leu-->Arg and leu-->Gln mutants. Our results suggest that Leu222 in the KALKK sequence of the IC3 of the hAT1 receptor, through not essential for antagonist binding, has an essential role in mediating interactions with G protein and in signal transduction.
Assuntos
Angiotensina II/metabolismo , Leucina/fisiologia , Receptores de Angiotensina/metabolismo , Transdução de Sinais , Animais , Células CHO , Células COS , Cricetinae , Ativação Enzimática , Humanos , Leucina/genética , Receptor Tipo 1 de Angiotensina , Receptor Tipo 2 de Angiotensina , Receptores de Angiotensina/genética , Fosfolipases Tipo C/metabolismoRESUMO
The G protein-coupled mu-opioid receptor (mu OR) mediates the physiological effects of endogenous opioid peptides as well as the structurally distinct opioid alkaloids morphine and etorphine. An intriguing feature of mu OR signaling is the differential receptor trafficking and desensitization properties following activation by distinct agonists, which have been proposed as possible mechanisms related to opioid tolerance. Here we report that the ability of distinct opioid agonists to differentially regulate mu OR internalization and desensitization is related to their ability to promote G protein-coupled receptor kinase (GRK)-dependent phosphorylation of the mu OR. Although both etorphine and morphine effectively activate the mu OR, only etorphine elicits robust mu OR phosphorylation followed by plasma membrane translocation of beta-arrestin and dynamin-dependent receptor internalization. In contrast, corresponding to its inability to cause mu OR internalization, morphine is unable to either elicit mu OR phosphorylation or stimulate beta-arrestin translocation. However, upon the overexpression of GRK2, morphine gains the capacity to induce mu OR phosphorylation, accompanied by the rescue of beta-arrestin translocation and receptor sequestration. Moreover, overexpression of GRK2 also leads to an attenuation of morphine-mediated inhibition of adenylyl cyclase. These findings point to the existence of marked differences in the ability of different opioid agonists to promote mu OR phosphorylation by GRK. These differences may provide the molecular basis underlying the different analgesic properties of opioid agonists and contribute to the distinct ability of various opioids to induce drug tolerance.
Assuntos
Proteínas de Ligação ao GTP/fisiologia , Proteínas Quinases/fisiologia , Receptores Opioides mu/fisiologia , Transdução de Sinais/fisiologia , Linhagem Celular , Etorfina/farmacologia , Técnicas de Transferência de Genes , Humanos , Morfina/farmacologia , Entorpecentes/agonistas , Entorpecentes/farmacologia , Receptores Opioides mu/agonistas , Transdução de Sinais/efeitos dos fármacosRESUMO
Angiotensin II (Ang II) regulates aldosterone production in bovine adrenal glomerulosa cells by interacting with the AT1 receptor. This receptor is coupled to a G protein that controls the activity of phospholipase C. With a primary culture of bovine adrenal glomerulosa cells, we evaluated the desensitization of cellular responses after pretreatment with Ang II. When cells were pretreated for 30 min with 1 microM Ang II at 37 C, we observed a 48% loss of [125I]Ang II-binding activity. Scatchard analysis revealed that this decreased binding activity corresponded to a 53% loss of the total number of binding sites. This phenomenon was time dependent, with a t(1/2) of 20 min, and a maximal loss of 76% of the total binding sites was observed after 14 h. A time-dependent decrease in AT1 receptor messenger RNA levels was also observed after pretreatment with 1 microM Ang II for 12-24 h. Taken together, these results are interpreted as a down-regulation of the AT1 receptor. Desensitization of phospholipase C activity under similar conditions was, however, a slower process, with a t(1/2) of 9 h and a maximal response reduction of 83% observed after 24 h. Dose-response experiments indicated that maximal phospholipase C desensitization was obtained in the presence of 1 microM Ang II, with an EC50 of 90 nM. The desensitization was of a homologous nature, as a 24-h pretreatment with Ang II did not affect bradykinin-induced inositol phosphate production. A 24-h pretreatment with 1 microM Ang II also significantly desensitized the steroidogenic effect of Ang II and the potentiating effect of Ang II on ACTH-induced cAMP production. Lower concentrations of Ang II (10 nM) did not produce any desensitizing effect on these two parameters. This study provides evidence that glomerulosa cells are functionally resistant to short term desensitization of the AT1 receptor and that long term down-regulation with high concentrations of Ang II is needed to desensitize AT1-mediated cellular responses.
Assuntos
Angiotensina II/farmacologia , Regulação para Baixo , Receptores de Angiotensina/efeitos dos fármacos , Receptores de Angiotensina/fisiologia , Zona Glomerulosa/metabolismo , Hormônio Adrenocorticotrópico/farmacologia , Aldosterona/biossíntese , Angiotensina II/administração & dosagem , Angiotensina II/metabolismo , Animais , Bradicinina/farmacologia , Bovinos , AMP Cíclico/biossíntese , Tolerância a Medicamentos , Fosfatos de Inositol/biossíntese , Cinética , RNA Mensageiro/metabolismo , Receptor Tipo 1 de Angiotensina , Receptor Tipo 2 de Angiotensina , Receptores de Angiotensina/genética , Zona Glomerulosa/efeitos dos fármacosRESUMO
We recently reported that replacement of Tyr302 for Ala in the human angiotensin II type 1 receptor (hAT1) severely impaired its ability to activate phospholipase C (PLC). Another study demonstrated that the same mutation in the rat AT1 receptor only slightly impaired its ability to activate PLC. The most striking difference between the two studies was the use of LiCl in the experimental conditions. Thus, in the present report we evaluated the effect of LiCl on the rate of accumulation of inositol trisphosphate (IP3) in transfected cells stimulated with angiotension II (Ang II). In the presence of LiCl, Ang II caused a significant accumulation of IP3 in COS-7 cells transfected with the hAT1Y302A mutant receptor. In stably expressing CHO cells, stimulation of hAT1Y302A did not induce any IP3 elevation even in the presence of LiCl whereas the hAT1 wild-type receptor increased the production of IP3 exclusively in the presence of LiCl. These results show that LiCl is a convenient tool to enhance the sensitivity of PLC assays. However, in structure-activity relationship studies, it may underestimate or mask the debilitating effect of some mutations.
Assuntos
Cloreto de Lítio/farmacologia , Compostos Organotiofosforados/metabolismo , Receptores de Angiotensina/metabolismo , Fosfolipases Tipo C/metabolismo , Substituição de Aminoácidos , Angiotensina II/metabolismo , Angiotensina II/farmacologia , Animais , Células CHO , Células COS , Cricetinae , Ativação Enzimática , Inositol 1,4,5-Trifosfato/análogos & derivados , Inositol 1,4,5-Trifosfato/metabolismo , Cloreto de Lítio/metabolismo , Mutagênese Sítio-Dirigida , Receptor Tipo 1 de Angiotensina , TransfecçãoRESUMO
Structural analysis of G-protein-coupled receptors has largely been limited to photoaffinity labeling and site-directed mutagenesis. This is primarily due to the difficulty in the production of antibodies against this class of receptors. We were therefore interested in tagging the amino-terminal side of the human angiotensin II (AngII) type 1 receptor (AT1) with the FLAG epitope DYKDDDDK. Competitive binding experiments with [125I][Sar1,Ile8]AngII revealed that stably transfected Chinese hamster ovary (CHO) cells express 37,300 hAT1-FLAG receptors/cell with a high affinity of 0.53 nM, comparable with that of the wild-type hAT1. After photolabeling and solubilization, a significant proportion of hAT1-FLAG specifically immunoprecipitated with anti-FLAG M5 and M2 antibodies. The immunoprecipitated receptor comigrated on SDS-PAGE with photolabeled wild-type hAT1. Immunofluorescence studies by FACS scan analysis revealed that 11.9% of CHO cells expressing hAT1-FLAG receptor significantly increased their fluorescence level as a result of M5 specific reactivity. Western blot analysis failed to show any specific interaction between M5 antibody and denatured hAT1-FLAG receptor. These results demonstrate the efficiency of the epitope tagging approach for specific immunoreactivity against AT1 receptor. Appropriate refinements of this approach could improve the level of immunoreactivity.